BriaCell Therapeutics Corp BCTX 深 沪
已收盘 11-06 16:00:00 美东时间
3.95
+0.680
+20.80%
华盛通- 最 高4.08
- 今 开3.34
- 成交量 16.05万股
- 最 低 3.30
- 昨 收 3.27
- 总市值 3449.29万
- 52周最高 13.09
- 市盈率 静 --
- 换手率 1.84%
- 52周最低 2.60
- 委 比 0.00%
- 总股本 873.24万
- 历史最高 1860.5799
- 量 比 2.00
- 振 幅 23.85%
- 历史最低 2.60
- 每 手 1
- 风险率 2.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
BriaCell Therapeutics and its subsidiary BriaPro announced four preclinical research presentations at the SITC 2026 Annual Meeting. The presentations focus on BriaCell’s Bria-OTS+ cellular immunotherapy platform and BriaPro’s CD80-based programs, including BP-80, TILsRx-001, and engineered CD80 variants. Bria-OTS+ demonstrated immune activation and tumor killing across breast, prostate, and lung cancer models. BriaPro data highlights BP-80’s tole...
11-03 14:00
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
BriaCell Therapeutics Corp. presented findings at the ESMO Congress 2026 showing that dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAMLs) correlate with progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer patients treated with immunotherapies, including the Bria-IMT regimen. The prospective pooled analysis of 111 patients demonstrated significant associations between...
10-23 11:30
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
BriaCell Therapeutics and its subsidiary BriaPro Therapeutics announced the selection of four abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in November 2026. The presentations will highlight BriaCell's personalized off-the-shelf immunotherapy, Bria-OTS+™, and BriaPro's research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants. The posters will be...
10-06 11:30
Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK) BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDA...
09-08 19:35
BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone
Cell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing Program builds on BriaCell’s experience in metastatic bre...
08-24 19:33
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
BriaCell Therapeutics Corp. announced the advancement of Bria-MEL+, a personalized, off-the-shelf melanoma immunotherapy vaccine, achieving a key genetic engineering milestone. Bria-MEL+ harnesses patients' immune systems by matching premanufactured cell lines with patient HLA types, aiming to enhance accessibility, reduce costs, and shorten treatment timelines. The program builds on BriaCell's success in metastatic breast and prostate cancers. M...
08-24 11:30
BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell’s next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designe...
08-05 19:33
BriaCell Therapeutics Enters Manufacturing Arrangement With FUJIFILM Biotechnologies To Support Phase 3 Clinical Development And Potential Future Commercial Supply Of Its Allogenic Cell Therapy BRIA-IMT
Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). "Securing manufacturing capacity with Fujifilm, a global leader in cell therapy ...
07-15 19:35
BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMT
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (NASDAQ:CRAI) and Kaleio, Inc. to support co...
07-07 19:32
BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMT
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has entered into a Memorandum of Understanding ("MoU"), with Uneedle, a microneedle based drug-delivery device ...
06-25 19:40
